# Santa Ana Bio

**Canonical:** https://apis.io/providers/santa-ana-bio/  
**Website:** https://www.santaana.bio/  
**APIs profiled:** 0

Santa Ana Bio is a precision immunology company developing targeted therapies to stop autoimmune and inflammatory disease at the source. The company pairs a multi-omics discovery platform (integrating genomic, transcriptomic, and proteomic data) with a pipeline of bispecific and multi-specific antibody and antibody-drug-conjugate programs (SAB01, SAB05, SAB06) advancing toward IND submissions across 2026-2027. Backed by a16z and GV, it was added to the API Evangelist network as a portfolio company. It publishes a corporate and careers website but no public developer, API, or documentation surface.

## Kin Score — 9.2 / 100 (minimal)

Scored 2026-08-21 under rubric 0.12.0. Trend: flat (+0.0 from 9.2).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Santa Ana Bio Domain Security** — TLSv1.3

## Tags

Company, Biotechnology, Immunology, Autoimmune Disease, Drug Discovery, Precision Medicine, Multiomics, Therapeutics

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/santa-ana-bio/). Scores are computed from the provider's own public artifacts under a published rubric.
